期刊文献+

肿瘤抗血管生成治疗耐药的分子机制进展 被引量:1

Recent Advances in Molecular Mechanisms of Resistance to Tumor Anti-Angiogenic Strategies
下载PDF
导出
摘要 血管生成在肿瘤的进展、侵袭和转移中扮演着重要的角色。血管内皮生长因子是其中一个重要的调节因子,很多肿瘤表现为血管内皮生长因子高表达,并且与肿瘤的预后不良相关。目前针对抗血管生成治疗,一部分在初始治疗即出现耐药,而另外有些则在几个月的治疗后出现耐药。目前耐药的机制尚不完全明了。现综述肿瘤抗血管生成治疗耐药的分子机制的新进展。 Angiogenesis plays an essential role in tumor growth,invasion and metastasis.Vascular endothelial growth factor is one of the key factors responsible for its regulation.High expression of vascular endothelial growth factor has been observed in many cancers,and is associated with worse survival.Many tumors fail to respond initially.Others has resistance after a few months of treatment.The mechanisms of resistance are not well understood.Here is to reviews current knowledge on resistance mechanisms.
出处 《医学综述》 2011年第21期3256-3260,共5页 Medical Recapitulate
关键词 抗血管生成 肿瘤 耐药 Anti-angiogenic Tumor Drug resistance
  • 相关文献

参考文献35

  • 1Folkman J. Tumor angiogenesis : therapeutic implications [ J ]. N Engl J Med,1971,285(21 ) :1182-1186.
  • 2Allegra CJ,Yothers G,O'Connell M J,et al. Initial safety report of NSABP C-08 :a randomized phase Ⅲ study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage Ⅱ or Ⅲ colon cancer[J]. J Clin Oncol,2009,27(20) : 3385-3390.
  • 3Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition [ J ]. J Clin Invest, 2006,116(10) :2610-2621.
  • 4Ebos JM,Lee CR, Christensen JG, et al, Multiple circulating proan- giogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy[ J]. Proc Natl Acad Sci U S A ,2007,104(43 ) : 17069-17074.
  • 5Willett CG, Boueher Y, Duda DG,et al. Surrogate markers for anti- angiogenie therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy : continued experience of a phase I trial in rectal caneer patients [ J ]. J Clin Oncol, 2005,23 ( 31 ) : 8136-8139.
  • 6Fischer C, Jonckx B, Mazzone M, et al. Anti-PLGF inhibits growth of VEGF (R)-inhibitor-resistant tumors without affecting healthy vessels[ J ]. Cell ,2007,131 ( 3 ) :463-475.
  • 7Levina V, Su Y,Nolen: B,et al. Chemotherapeutic drugs and human tumor cells cytokine network [ J]. Int J Cancer, 2008,123 (9) : 2031-2040.
  • 8Kataoka N, Cai Q, Wen W, et al. Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women [ J ]. Cancer Epidemiol Biomarkers Prey, 2006,15 (6) :1148-1152.
  • 9Sfar S, Saad H, Mosbah F, et al. Combined effects of the angiogenic genes polymorphisms on prostate cancer susceptibility and aggres- siveness[ J]. Mol Biol Rep,2009,36 ( 1 ) :37-45.
  • 10Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor re- ceptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer:ECOG 2100[J]. J Clin Oncol,2008,26(28) :4672-4678.

同被引文献8

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部